SMT112-216: A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer (clinicaltrials.gov) - Oct 17, 2026 - P2 | N=100 | Not yet recruiting | Sponsor: Summit Therapeutics
New P2 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|